Season 2 (2021-2030)

Neuroscience - Discovery (23)

Modality Indication Targets Stage Company Project No. Detail
1 Discovery of PIP5Kgamma inhibitor for treatment of Parkinson's disease
Small Molecules Parkinson's disease PIP5Kγ Hit K.MEDI hub RS-2023-00283494
2 Development of gene.editing therapeutics for Huntington’s disease with CAG repeat expansion
Gene Therapy Huntington's disease HTT gene(CAG.repeat) Hit GenKOre RS-2023-00259174
3 Development of therapeutic agent for Parkinson's disease targeting alpha synuclein aggregates using autophagy targeting chimera (AUTOTAC)
Small Molecules Parkinson's disease α-Syn Hit AUTOTAC Bio Inc. RS-2022-00166787
4 Developing biomedicine to overcome neuropathic pain by GCH1 expression down-regulation
Gene Therapy Neuropatic Pain GCH1 Hit Yonsei University HN22C0307
5 Development of an exosome-mediated intracellular therapeutic protein delivery system for Parkinson's disease
Others Parkinson's disease Parkin, PGC-1α Hit Sungkyunkwan University HN21C1266
6 Development of a lead compound for preventing Parkinson’s disease using small compounds with inhibitory mechanism of initial alpha-synuclein aggregation
Small Molecules Parkinson's disease α-synuclein Hit Hanyang University HN21C1258
7 Bone-delivered therapeutic antibody for osteoporosis based on clinically verified, innovative mode of action
Antibody Osteoporosis Cathepsin K Hit Ewha Women's University HN21C0317
8 Development of lead compound for treatment of hearing loss caused by cisplatin
Small Molecules Hearing loss DRAK1, ADCK4, CDC42BPA Hit Kyungpook National University HN21C0107
9 Development of lead compounds as antidepressant having both α2 adrenergic antagonist and NDRI activities
Small Molecules Major depressive disorder A2 adrenergic, NDRI Hit Kyung Hee University HN21C1076
10 Discovery of Lead Candidates for Parkinson’s disease targeting novel TAS2R GPCR
Small Molecules Parkinson's disease TAS2R Lead DIGMBIO RS-2023-00219269
11 Discovery of a novel lead compound for chronic pain treatments using a TRPV1 binding peptides design and manufacture platform
Peptide Chronic Pain TRPV1 Lead Gachon University RS-2022-00167087
12 The lead selection study of TLR2 targeted antisense oligonucleotide 
using PNA as a therapeutic agent for Parkinson’s Disease (PD)
Nucleic acid/Virus Parkinson's Disease TLR2 Lead SEASUN THERAPEUTICS, Inc. HN22C0411
13 Discovery of a lead compound utilizing exon skipping platform for the treatment of 
amyotrophic lateral sclerosis
Nucleic acid/Virus Amyotrophic Lateral Sclerosis STMN2 Lead OliPass corporation HN22C0017
14 Lead identification of ASK1 inhibitor as a therapeutic agent for Parkinson’s disease
Small Molecules Parkinson's disease ASK1 Lead Korea Research Institute of Chemical Technology HN21C1139
15 Discovery of Lead Compounds for the Treatment of Progressive Supranuclear Palsy by Controlling 4R Tauopathy
Small Molecules Progressive supranuclear palsy, 4R tauopathies 4R tau oligomer Lead Korea Institute of Science and Technology HN21C0315
16 Development of treatment for neurodevelopmental disorder (Rett syndrome) based on RNA replacement technology using the next-generation efficacy evaluation method
Gene Therapy Rett syndrome MeCP2 Lead Rznomics Inc. HN21C1329
17 Development of KV7.4 specific activator for the treatment of genetic hearing loss(DFNA2)
Small Molecules Genetic Hearing Loss KV7.4 Lead Yonsei University HN21C0163
18 Development of AAV.based regenerative medicine expressing HGF gene (AAV9.HGF) for the treatment of ALS disease
Gene Therapy Amyotrophic Lateral Sclerosis HGF/c.Met signaling pathway Candidate Helixmith Co.,Ltd. RS-2023-00283601
19 Development of therapeutic antibody for the treatment of myasthenia gravis
Antibody Myasthenia gravis Disclosure after confidentiality agreement Candidate Medytox Inc. RS-2023-00283006
20 Development of ASO therapeutics to treat childhood intractable epilepsy
Gene Therapy Pediatric epilepsy MTOR Candidate Sovargen Co., Ltd. RS-2023-00282544
21 Discovery the preclinical candidate for amyotrophic lateral sclerosis (ALS) based on the activation of lysosomes using small-molecular proteins
Peptide Amyotrophic lateral sclerosis Zn2+ Candidate ZINCURE RS-2023-00218770
22 Investigation of proper candidates for in vivo direct lineage reprogramming based SCI gene therapy development
Gene Therapy Spinal cord injury astrocyte Candidate Stand Up Therapeutics RS-2022-00167083
23 Development of small molecule LRRK2 inhibitor for Parkinson’s disease treatment
Peptide Parkinson's disease LRRK2 Candidate Whan In Pharm. Co., Ltd. HN21C0655
BACK